

























































Biological Characterization, Mechanistic Investigation and
Structure-Activity Relationships of Chemically Stable TLR2
Antagonists
Marcel Bermudez+,[a] Maria Grabowski+,[b] Manuela S. Murgueitio,[a] Markus Tiemann,[a]
Péter Varga,[a] Thomas Rudolf,[a] Gerhard Wolber,*[a] Günther Weindl,*[b, c] and
Jörg Rademann*[a]
Toll-like receptors (TLRs) build the first barrier in the innate
immune response and therefore represent promising targets for
the modulation of inflammatory processes. Recently, the
pyrogallol-containing TLR2 antagonists CU-CPT22 and MMG-11
were reported; however, their 1,2,3-triphenol motif renders
them highly susceptible to oxidation and excludes them from
use in extended experiments under aerobic conditions. There-
fore, we have developed a set of novel TLR2 antagonists (1–9)
based on the systematic variation of substructures, linker
elements, and the hydrogen-bonding pattern of the pyrogallol
precursors by using chemically robust building blocks. The
novel series of chemically stable and synthetically accessible
TLR2 antagonists (1–9) was pharmacologically characterized,
and the potential binding modes of the active compounds
were evaluated structurally. Our results provide new insights
into structure-activity relationships and allow rationalization of
structural binding characteristics. Moreover, they support the
hypothesis that this class of TLR ligands bind solely to TLR2 and
do not directly interact with TLR1 or TLR6 of the functional
heterodimer. The most active compound from this series (6), is
chemically stable, nontoxic, TLR2-selective, and shows a similar
activity with regard to the pyrogallol starting points, thus
indicating the variability of the hydrogen bonding pattern.
Introduction
The first barrier in the innate immune response is formed by
the family of structurally conserved Toll-like receptors (TLRs).[1]
In humans ten functional subtypes (TLR1–TLR10) have been
identified. TLRs recognize intruding pathogens or endogenous
danger signals released after cell damage or cell death and
activate the innate immune response against them. This
happens through the specific binding of pathogen-associated
molecular patterns (PAMPs) and danger-associated molecular
patterns (DAMPs), respectively.[2] TLR2 forms heterodimers with
TLR1 and TLR6 and specifically recognizes several components
of the cell wall of gram positive bacteria like di- and tri-acylated
lipoproteins, lipoteichoic acids or lipomannans. After ligand
binding, the preformed dimer undergoes conformational
changes that trigger an intracellular signaling cascade that
leads to the activation of NF-kB and the secretion of pro-
inflammatory cytokines like tumor necrosis factor (TNF) and
interleukin (IL)-8.[3] Under certain circumstances this response is
excessive and leads to severe conditions like sepsis, rheumatoid
arthritis, autoimmune diabetes, asthma and certain types of
allergies.[1,4] The modulation of TLR2 function by small mole-
cules has been postulated as a promising strategy to treat these
conditions. To date only few compounds that modulate TLR2
activity have been identified and pharmacologically character-
ized. In 2010, four small organic molecules with agonistic
activity on the receptor were discovered by high-throughput
screening by Guan et al.[5] One of them was later chemically
optimized.[6] In 2012 the first competitive antagonist CU-CPT22
was discovered by Yin et al. (Figure 1, left).[7] Virtual screening
has successfully been applied to discover agonists and antago-
nists for TLR2,[8] but also for other TLR subtypes.[9] In a previous
study, we identified a potent, competitive and selective TLR2
antagonist MMG-11;[10] however, it still contained the pyrogallol
fragment (Figure 1, right). As the pyrogallol scaffold is notorious
for its drawbacks including low chemical stability and poor
synthetic accessibility, the modification of this scaffold to one
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that is less prone to oxidation is essential for further
optimization steps.
In this work, we explored the chemical space around the
pyrogallol-containing antagonists, MMG-11 and CU-CPT22, to
enhance synthetic accessibility and chemical stability, and get
insights into the structure-activity-relationships (SARs) of TLR2
antagonists. We performed synthetic modifications and ana-
logue searches. The synthesized small molecules and selected
analogues were biologically tested for their ability to inhibit
TLR2 signaling. This leads to several novel TLR2 antagonists, a
better understanding of their SAR and provides a way to
rationalize binding modes of TLR2 antagonists.
Results and Discussion
Compound selection, design and synthesis
A selection of the compounds that resulted from both chemical
synthesis and similarity-based analogue search is shown in
Scheme 1. The design was guided by binding mode investiga-
tions of MMG-11 in complex with TLR2 regarding spatial
requirements of the binding site and potential receptor-ligand
interactions. Especially, we intended to modify the polyphenolic
core structure, with the aim of avoiding the most easily oxidized
1,2-diphenols and 1,2,3-triphenols or the phenoxy ethers
derived from them. Since the three hydroxy groups of the
pyrogallol scaffold are involved in hydrogen bonding with the
receptor (Figure 2A),[10a] we had to systematically evaluate these
interactions. Therefore, we reduced the number of hydroxy
groups capable to function as both hydrogen bond donors and
acceptors (1, 3, 5 and 6) and varied the substitution pattern. For
a systematic control, two compounds still comprising the 1,2,3-
trihydroxy motif, 7 and 8, were included in the study.
Furthermore, we introduced methoxy groups, which can only
serve as hydrogen bond acceptors (2 and 4). Considering the
flexibility of the lead structure, we introduced an amide moiety
to rigidify the molecules (1–4 and 6). In order to enhance
synthetic accessibility and the chemical stability, we exchanged
the furan moiety by a phenyl ring in all synthesized com-
pounds. This resulted in a set of eight synthesis-derived
compounds (1–8, Schemes 1 and 2 and the Supporting
Information).
In a complementary approach we searched for structural
analogues in the databases which were used for the discovery
of MMG-11 by virtual screening.[10a] MMG-11 was used as the
query structure and the databases were searched for similar
commercially available molecules with a Tanimoto coefficient
higher than 0.8. We found three closely related compounds in
the Enamine database (Enamine Ltd, Kiev, Ukraine) which were
ordered for biological evaluation (9–11). Molecular weight and
purity (>95%) were confirmed by LC–MS.
The resulting set of eleven derivatives obtained by synthesis
and analogue search, provides the possibility to conceive the
SAR of TLR2 antagonists, in particular for the rationalization of
the hydrogen bond pattern of polyphenolic ligands.
Compounds 1, 3, and 6 were synthesized starting from the
corresponding 2,4-, 3,4-, or 3,5-dihydroxy-benzoic acids as
exemplified for compound 6 in Scheme 2. First, both the
phenolic hydroxy groups and the carboxylic acid residues were
protected in one step as O-benzyl-ethers and esters, respec-
tively, using benzyl bromide with iodide addition and furnishing
the tri-O-benzyl-protected intermediates 12–14.
The tri-O-methyl-protected 3,4-dihydroxy benzoic acid 15
needed for the synthesis of compound 2 was prepared by an
analogous protocol using methyl iodide for alkylation. Saponifi-
Figure 1. Previously discovered competitive TLR2 antagonists CU-CPT22 and
MMG-11 both containing the pyrogallol scaffold.[7,10a]
Scheme 1. Synthesized and selected compounds. The starting point MMG-
11 is depicted on the top with the different variations highlighted in color.
Compounds 1 to 8 were rationally designed and synthesized and are shown
on the left side. The compounds selected by analogue search (9 to 11) are
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cation of the esters 12–15 afforded the free carboxylic acids
16–19 in very good yields (95% quantitatively). Next, the
prepared carboxylic acids 16–19 or commercially available 3,4-
dimethoxy-phenylacetic acid were activated using O-(7-azaben-
zotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophos-
phate (HATU) in the presence of ethyl 3-aminobenzoate 20
yielding the protected benzamides 2, 4, and 21–23 as the
desired condensation products. Here the yields were moderate,
presumably due to the reduced nucleophilicity of the aromatic
amine in 20. Hydrogenolysis with palladium on charcoal
removed the benzyl ether groups and furnished the unpro-
tected benzamides 1, 3, and 6 in very good yields, for example,
86% for compound 6.
Aromatic ketone 5, in which the amide linker between two
benzene rings is replaced by a ketomethylene unit, was
obtained via the direct C-acylation of resorcinol (1,3-diphenol)
with 3,4-dimethoxy-phenyl acetic acid using boron trifluoride
diethyl etherate as the activating Lewis acid in 19% yield.
Compounds 1–6 were isolated with >95% purity by column
chromatography. Synthesis of the trihydroxy-derivatives, ethyl
3-(2,3,4-trihydroxy-benzamido)benzoate 7 and ethyl 3-(3,4,5-
trihydroxy-benzamido)benzoate 8 was attempted following the
same strategy as in Scheme 2. While the preparation of the tri-
O-benzyl-protected precursors of 7 and 8 proceeded smoothly,
debenzylation of the protected intermediates led to the
instantaneous decomposition of these products due to oxida-
tion. 7 and 8 therefore could not be isolated and tested
biologically.
Biological validation
To explore the activity of the synthesized and selected
compounds 1 to 6 and 9 to 11 on the TLR2 activity, reporter
cells overexpressing hTLR2 were used. CU-CPT22 was used as
the reference TLR2-antagonist.[7,10a, 11] Except for 1, all selected
compounds decreased TLR2-mediated NF-kB activation in a
primary screen (Figure 3A). Additionally, 4, 6, 9 and 10 reduced
Pam3CSK4-induced TLR2/1 responses to less than 40% at 50 μM
and 2–6, 9 and 10 diminished Pam2CSK4-induced TLR2/6
responses to less than 50% at 50 μM. Compound 6 and 11
abrogated the TLR2 response of both heterodimers almost
completely and therefore showed a similar TLR2 inhibition as
CU-CPT22 (Figure 3A). None of the tested compounds appeared
to have any agonistic TLR2 activity (Figure S1A in the Support-
ing Information).
Figure 2. Predicted binding pose for MMG-11 and 6. The TLR2 antagonists A) MMG-11 and B) 6 bound in the TLR2 ligand binding site are shown. Protein
residues are depicted in ball and stick mode, the compound as sticks. Protein-ligand interactions are color- and shape-coded (yellow sphere – hydrophobic
contact area, green arrow – H-Bond donor, red arrow – H-Bond acceptor).
Scheme 2. Synthesis of inhibitor 6. a) BnBr, K2CO3, acetone, reflux, 8 h; b)
NaOH, MeOH, H2O, reflux, 8 h, quant. over 2 steps. c) SOCl2, EtOH, reflux, 4 h,






1366ChemMedChem 2020, 15, 1364–1371 www.chemmedchem.org © 2020 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA
Wiley VCH Mittwoch, 15.07.2020


























































No cytotoxic effects were observed within the activity range
except for 11 which reduced cell viability starting at 50 μM
(Figure S1B). Hence, the apparent inhibition of TLR2-mediated
responses by 11 might be due its cytotoxicity. Consequently,
compound 11 was excluded from further investigation. The
remaining most active hits, 4, 6, 9 and 10, were analyzed
regarding their potency. For this purpose, concentration-
response curves were assessed and IC50 values were calculated
(Figure 3B). All four compounds showed IC50 values in the μM
range, thus confirming their antagonistic effect as MMG-11
analogues (Table 1). Compound 6 turned out to have the lowest
IC50 value of the identified TLR2 inhibitors with similar results
for both heterodimers (TLR2/1: 15.4 μM; TLR2/6: 13.6 μM). This
suggests binding of compound 6 to the TLR2 cavity but no
interaction towards TLR1 or TLR6. While compound 6 effectively
inhibits TLR2 signaling, we could show that it has no influence
on other TLR subtypes (Figure 3C). While keeping the activity of
compound 6 in a comparable range as for CU-CPT22 and MMG-
11, we could replace the highly sensitive 1,2,3-trihydroxyphenyl
structure of pyrogallol in the starting compounds by the
chemically stable 1,3-dihydroxyphenyl substructure of resorci-
nol. This is essential for further optimization of TLR2 antagonists
Figure 3. Inhibition of TLR2-dependent NF-kB activation and IL-8 secretion. A) HEK-Blue hTLR2 cells were pre-incubated with CU-CPT22 or compounds 1–6
and 9–11 for 1 h and then stimulated additionally with TLR2/1 agonist Pam3CSK4 (10 ng/mL) or TLR2/6 agonist Pam2CSK4 (1 ng/mL) for 24 h. B) HEK-Blue
hTLR2 cells were pre-incubated with increasing concentrations of 4, 6, 9, 10 and then stimulated additionally with Pam3CSK4 or Pam2CSK4 for 24 h.
Supernatants were tested for TLR2-mediated NF-kB/AP-1 activity by quantification of SEAP release (OD640). C) THP-1 macrophages were incubated with CU-
CPT22 (25 μM) or compound 6 for 1 h and afterwards stimulated with Pam3CSK4 (10 ng/mL), Pam2CSK4 (1ng/mL), LPS (10 ng/mL), flagellin (1 μg/mL), CL075
(8 μM) or ODN2006 (5 μM) for 24 h. Supernatants were analyzed for IL-8 secretion by ELISA. Mean+SD or �SD (n=3).
Table 1. IC50 values of the compounds 4, 6, 9 and 10 by TLR2/1 stimulation
(Pam3CSK4, 10 ng/mL) and TLR2/6 stimulation (Pam2CSK4, 1 ng/mL) in HEK-







4 44.9 (28.1–72.0) 61.9 (18.7–204.6)
6 15.4 (8.9–26.4) 13.6 (9.9–18.6)
9 42.4 (36.9–48.7) 42.9 (36.9–49.9)
10 44.0 (33.8–57.4) 40.7 (30.9–53.6)
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because 6 is robust, synthetically accessible and no longer
susceptibility toward oxidation.
SAR of novel antagonists
In order to rationalize the bioactivity and elucidate the potential
binding modes of the tested compounds docking studies were
performed. As all characterized compounds both inhibited
TLR2/1 and TLR2/6 signaling, without showing effects at other
TLRs, we hypothesized that they would bind to the TLR2
monomer and share the same ligand binding pocket like its
pyrogallol-containing precursor, MMG-11.[10a] This compound
has been previously shown to be a competitive antagonist for
the binding of Pam3CSK4 and Pam2CSK4, which further supports
our proposed binding mode. However, an experimental con-
firmation of the binding mode is beyond the scope of this
study. Extensive docking analyses were performed and plau-
sible binding poses selected based on their similarity to the
binding mode of MMG-11 and the amount of performed
interactions between the ligand and the TLR2 binding site. The
resulting proposed binding mode for the most active com-
pound 6 is shown in Figure 2B. Selected docking poses for the
remaining compounds can be found in the Figures S2 to S5. 6 is
embedded in the front part of the binding pocket with the
dihydroxy-benzamide moiety forming several H-Bonds to the
backbone atoms of TLR2. The benzene ring forms hydrophobic
contacts to the Phe325 side chain.
Deeper in the pocket further hydrophobic contacts take
place between the benzoate and Leu328, Val313 and Ile314 and
the ethyl moiety and Phe284, Leu317, Leu285, Ile261, Leu266
and Ile314. H-bond acceptor interactions are formed by the
hydroxy group on position 5 and the backbone nitrogen atoms
of Leu350 and Phe349, in addition to an H-Bond donor
interaction between the second hydroxy group in position 3
and backbone oxygen of Ser346. These H-Bonds are also
formed by MMG-11 (Figure 2A) and have been shown to be
important for antagonists binding to TLR2.[8e] This might explain
the lower activity of the other dihydroxybenzamidobenzoates
(1 and 3, Figure S2) and the dimethoxybenzamidobenzoates (2
and 4, Figure S3). The geometry of the 2,4-dihydroxy-benza-
mide 1 causes it to form H-Bonds to Ser346 and Lys347 but not
Leu350 and Phe349 leading to a weak activity. The 3,4-
dihydroxy-benzamide 3 is more active than 1 as the mandatory
H-Bonds to Leu350 and Phe349 are formed, but less active than
6 as the stabilizing H-Bond to Ser326 is missing. In the case of
the dimethoxybenzamidobenzoates the methoxy groups are
worse and bulkier acceptors than the hydroxy groups thus
making the formation of the key H-Bonds less favorable. For
these compounds we hypothesize a flipped binding mode
which allows the carbonyl oxygen of the ester to interact with
the backbone of Phe349 and Leu350, without the formation of
further stabilizing H-Bonds towards Ser346 the resulting activity
still is low. The dihydroxyphenyl moiety of compound 5 is
surmised to form two H-Bonds towards Phe349 and Leu350,
however its scaffold puts the methoxy groups into proximity of
hydrophobic residues, which is unfavorable for binding and
leads to a reduced activity (Figure S4).
In addition to the synthesized compounds we tested three
dihydroxy-phenyl-oxoethyl-furan-carboxylates (9, 10 and 11) of
which one 11 was cytotoxic and therefore omitted in further
analysis. The other two compounds, 9 and 10 show a binding
mode nearly identical to that of MMG-11 (Figure S5). Surpris-
ingly, their activity is much lower, which shows the importance
of the third hydroxy group for the stabilization of ligands
containing the furan carboxylate scaffold. Interestingly, this is
not the case for the newly developed and rigidified dihydrox-
ybenzamidobenzoates like lead structure 6, which virtually
retains the binding affinity despite of having only two
remaining hydroxy groups.
Conclusion
Taken together, this study reports a set of TLR2 antagonists
derived by chemical synthesis and analogue search based on
the previously reported pyrogallol-containing TLR2 antagonists
CU-CPT22 and MMG-11. The series of compounds (1–11)
designed and tested here provides novel insights into the
structure-activity relationships of TLR2 antagonists and allows
for rationalization of structural binding characteristics. The
findings prove the possibility of varying the pyrogallol frag-
ment, the hydrogen bonding pattern, the second aryl aryl
fragment and the linker moiety connecting both fragments.
These tolerated variations enabled the development of chemi-
cally stable drug candidates without the sensitive pyrogallol
scaffold. The nontoxic and most active compound from this
series, inhibitor 6, shows a comparable activity toward TLR2 as
its pyrogallol precursors without being sensitive toward
oxidative degradation like its pyrogallol derivatives. Further-
more, the biological activity of this inhibitor supports our
hypothesis that this group of TLR antagonists binds solely to
TLR2 and does not directly interact with the TLR1 or TLR6 part
of the functional heterodimer.
Experimental Section
Chemical synthesis: Chemicals were purchased from Acros, Alfa
Aesar, Fluka, Sigma-Aldrich, and VWR and were used without
further purification or distillation unless otherwise stated. All
solvents that were used during the reactions were obtained from a
column-based solvent system (MBraun, MB-SPS-800). Air or mois-
ture-sensitive reactions were carried out under a positive pressure
of dry nitrogen or argon in oven-dried glassware. Solution phase
reactions were monitored either by LC-MS techniques or by thin-
layer chromatography (TLC) using Analtech silica gel plates (60
F254) and the spots were examined under UV light at 254 nm or
stained with developing reagents. LC-MS data were recorded on an
Agilent 1100 series chromatography workstation (Agilent Technolo-
gies) equipped with a single quadruple mass spectrometer and
electrospray ionization (ESI). Eluents A (0.1% formic acid in Millipore
water) and B (0.1% formic acid in acetonitrile) were used in a linear
gradient (5–99% B in 5 min). Solvents were removed in rotary
evaporators from Heidolph. The Biotage®IsoleraTM Spektra One was




1368ChemMedChem 2020, 15, 1364–1371 www.chemmedchem.org © 2020 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA
Wiley VCH Mittwoch, 15.07.2020


























































raphy cartridges from Biotage® employing individual gradients
derived from analytical runs or thin layer chromatography (TLC).
Non-HRMS measurements were recorded with an ESI single quad
spectrometer (Agilent) coupled with an analytical HPLC system
(Agilent 1100). HRMS measurements were conducted with an
Agilent 6210 ESI-TOF mass spectrometer. NMR spectra (1H and 13C
NMR) were recorded on a Bruker AVANCE 300 MHz, 400 MHz and
500 MHz instrument and chemical shifts (δ) were measured in parts
per million (ppm). The elemental analyzer VARIO EL was used for C,
H, and N analysis. Details for compound synthesis and analytic data
are given in the Supporting Information.
General procedure for the preparation of perbenzylated benzoic
acid esters 12–14: Benzyl bromide (6 equiv), sodium iodide
(6 equiv) and potassium carbonate (8 equiv) were added to a
solution of the respective benzoic acid in acetone (40 mL mmol  1)
at room temperature. The mixture was stirred under reflux for 16 h.
Then it was cooled to room temperature and the solvent removed
under reduced pressure. Water was added and the resulting
mixture was extracted with EtOAc. The combined organic layers
were dried over anhydrous Na2SO4 and filtered. EtOAc was
evaporated under reduced pressure and the resulting crude
product was purified by column chromatography over SiO2
(hexane/EtOAc as eluent) to afford the desired perbenzylated
compounds.
Benzyl 2,4-bis-(benzyloxy)benzoate (12): Compound 12 was
synthesized according to the general procedure using 2,4-dihydrox-
ybenzoic acid (1.00 g, 6.5 mmol) and was obtained as a pale yellow
solid (1.58 g, 3.72 mmol, 57%). 1H NMR (400 MHz, CDCl3): δ=7.91
(d, J=8.7 Hz, 1H), 7.46–7.28 (m, 15H), 6.61 (s, 1H), 6.58 (d, J=8.7 Hz,
1H), 5.32 (s, 2H), 5.11 (s, 2H), 5.06 (s, 2H).
Benzyl 3,4-bis-(benzyloxy)benzoate (13): Compound 13 was
synthesized according to the general procedure using 3,4-dihydrox-
ybenzoic acid (5.00 g, 32.5 mmol) and was obtained as a pale
yellow solid (7.80 g, 18.53 mmol, 57%). 1H NMR (400 MHz, CDCl3):
δ=7.71–7.65 (m, 2H), 7.49–7.31 (m, 15H), 6.93 (d, J=8.9 Hz, 1H),
5.32 (s, 2H), 5.22 (s, 2H), 5.20 (s, 2H).
Benzyl 3,5-bis-(benzyloxy)benzoate (14): Compound 14 was
synthesized according to the general procedure (without NaI) by
using 3,5-dihydroxybenzoic acid (0.77 g, 5 mmol) and was obtained
as a pale yellow solid (0.41 g, 0.95 mmol, 19%). 1H NMR (500 MHz,
[D6]DMSO): δ=7.46–7.31 (m, 15H), 7.18 (s, 2H), 6.98 (s, 1H), 5.33 (s,
2H), 5.15 (s, 4H).
Methyl 3,4-dimethoxy-benzoate (15): To a solution of 3,4-
dihydroxy-benzoic acid (0.80 g, 5.2 mmol, 1 equiv) in DMF (30 mL)
was added methyl iodide (1.50 mL, 25 mmol, 5 equiv) and
potassium carbonate (3.59 g, 25 mmol, 5 equiv) at room temper-
ature. The mixture was stirred at 50 °C for 16 h, cooled to room
temperature and concentrated under reduced pressure. Water was
added and the resulting mixture extracted with EtOAc (3×20 mL).
The combined organic layers were dried over anhydrous Na2SO4
and filtered. The EtOAc was evaporated under reduced pressure
and the resulting crude product purified by column chromatog-
raphy on SiO2 (hexane/EtOAc as eluent) to afford 15 as a white solid
(0.73 g, 3.74 mmol, 72%). 1H NMR (400 MHz, CDCl3): δ=7.65 (d, J=
8.4 Hz, 1H), 7.52 (s, 1H), 6.86 (d, J=8.4 Hz, 1H), 3.91 (s, 6H), 3.87 (s,
3H).
Preparation of benzoic acids 16–18. General procedure: To a
suspension of the appropriate benzyl benzoates (12–14) in EtOH at
room temperature was added an excess of 5 M NaOH solution and
the resulting mixture stirred under reflux for 8 h. The reaction
mixture was cooled to room temperature and acidified to pH 3 by
dropwise addition of 12 M HCl. The resulting precipitate was
filtered off, washed with water and dried under reduced pressure
to afford the corresponding acids 16–18.
2,4-Bis-(benzyloxy)benzoic acid (16): Compound 16 was synthe-
sized according to the general procedure, using 12 (1.01 g,
2.36 mmol). The resulting precipitate was recrystallized from
MeOH/CH2Cl2 (50 :1) and afforded 16 as a white solid (0.80 g,
1,89 mmol, 80%). 1H NMR (400 MHz, [D6]DMSO): δ=12.27 (s, 1H),
7.72 (d, J=8.6 Hz, 1H), 7.54–7.27 (m, 10H), 6.82 (s, 1H), 6.67 (d, J=
8.8 Hz, 1H), 5.20 (s, 2H), 5.16 (s, 2H).
3,4-Bis-(benzyloxy)benzoic acid (17): Compound 17 was synthe-
sized according to the general procedure, using 13 (2.30 g,
5.42 mmol) and was obtained as a white solid (1.70 g, 5.09 mmol,
94%). 1H NMR (400 MHz, [D6]DMSO): δ=12.57 (s, 1H), 7.46 (s, 1H),
7.45 (d, J=7.4 Hz, 1H), 7.39–7.19 (m, 10H), 7.06 (d, J=8.8 Hz, 1H),
5.12 (s, 2H), 5.08 (s, 2H).
3,5-Bis-(benzyloxy)benzoic acid (18): Compound 18 was synthe-
sized according to the general procedure, using 14 (0.21 g,
0.50 mmol) and was obtained as a white solid comprising a mixture
of acid and sodium salt (0.21 g, quant.). 1H NMR (500 MHz, [D6]
DMSO): δ=13.04 (s, 1H) 7.46–7.32 (m, 10H), 7.16 (s, 2H), 6.93 (s, 1H),
5.14 (s, 4H).
Preparation of 3,4-dimethoxy-benzoic acid (19): To a suspension
of 15 (0.35 g, 1,79 mmol, 1 equiv) in H2O/MeOH (1 :1 v/v, 30 mL) at
room temperature was added LiOH monohydrate (0.23 g,
5.36 mmol, 3 equiv) and the resulting mixture stirred for 4 h. The
reaction mixture was then brought to pH 3 using 1 M HCl and
extracted with EtOAc. The combined organic layers were dried over
anhydrous Na2SO4 and filtered. The EtOAc was evaporated under
reduced pressure to afford 19 as a white solid (0.31 g, 1.70 mmol,
95%). 1H NMR (400 MHz, [D6]DMSO): δ=12.67 (s, 1H), 7.56 (d, J=
8.4 Hz, 1H), 7.44 (s, 1H), 7.03 (d, J=8.5 Hz, 1H), 3.82 (s, 3H), 3.79 (s,
3H).
Preparation of ethyl 3-amino-benzoate (20): Compound 20 was
synthesized according to literature.[1] Brown oil, yield: 92%,1H NMR
(400 MHz, CDCl3): δ=7.41 (d, J=7.7 Hz, 1H), 7.34 (s, 1H), 7.19 (dd,
J=7.8 Hz, 1H), 6.83 (d, J=8.0 Hz, 1H), 4.33 (q, J=7.1 Hz, 2H), 3.48 (s,
2H), 1.36 (t, J=7.1 Hz, 3H).
General procedure for the preparation of benzamides 2, 4, and
21–23: To a mixture of the appropriate acid (1 equiv) and 20
(1 equiv) in CH2Cl2 (5 mL mmol
  1) was added HATU (1.2 equiv) and
DIPEA (3 equiv) at 0 °C and after which it was stirred at 30 °C for 8 h.
The solvent was removed under reduced pressure, water was
added and the resulting mixture was extracted with EtOAc. The
combined organic layers were dried over anhydrous Na2SO4 and
filtered. The EtOAc was evaporated under reduced pressure and the
resulting crude product was purified by column chromatography
over SiO2 (hexane/EtOAc as eluent) to afford the desired amides 2,
4, 21–23.
Ethyl 3-(3,4-dimethoxy-benzamido)benzoate (2): Compound 2
was synthesized according to the general procedure by using 19
(0.05 g, 0.28 mmol) and was obtained as a yellow solid (0.63 g,
0.21 mmol, 76%). 1H NMR (400 MHz, CDCl3): δ=8.19–8.00 (m, 3H),
7.80 (d, J=7.5 Hz, 1H), 7.49 (s, 1H), 7.47–7.37 (m, 2H), 6.87 (d, J=
8.4 Hz, 1H), 4.35 (q, J=7.1 Hz, 2H), 3.92 (s, 6H), 1.37 (t, J=7.0 Hz,
3H). 13C NMR (101 MHz, CDCl3): δ=166.40, 165.59, 152.33, 149.29,
138.46, 131.34, 129.32, 127.21, 125.46, 124.73, 121.10, 119.76,
110.79, 110.45, 61.31, 56.18, 14.43; HRMS (ESI+) [M+H]+ C18H20NO5
calculated 330.1341 Da, found: 330.1344 m/z.
Ethyl 3-(2-(3,4-dimethoxyphenyl)acetamido)benzoate (4): Com-
pound 4 was synthesized according to the general procedure (but
extracted with CH2Cl2 instead of EtOAc), using 2-(3,4-dimeth-
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yellow solid (0.28 g, 0.83 mmol, 81%). 1H NMR (500 MHz, CDCl3):
δ=7.91–7.84 (m, 2H), 7.74 (d, J=7.7 Hz, 1H), 7.49 (d, J=7.2 Hz, 1H),
7.35 (t, J=7.8 Hz, 1H), 6.89–6.84 (m, 2H), 6.83 (s, 1H), 4.33 (q, J=
7.1 Hz, 2H), 3.88 (s, 3H), 3.87 (s, 3H), 3.68 (s, 2H), 1.35 (t, J=7.1 Hz,
3H); 13C NMR (126 MHz, CDCl3): δ=169.80, 166.30, 149.59, 148.74,
138.00, 131.26, 129.19, 126.66, 125.48, 124.37, 121.84, 120.65,
112.59, 111.84, 61.28, 56.03, 44.43, 14.38; HRMS (ESI+) [M+H]+
C19H22NO5 calculated 344.1498 Da, found: 344.1506 m/z.
Ethyl 3-(2,4-bis-(benzyloxy)benzamido)benzoate (21): Compound
21 was synthesized according to the general procedure, using 16
(0.06 g, 0.18 mmol) and was obtained as a brown solid (0.02 g,
0.04 mmol, 20%). 1H NMR (400 MHz, CDCl3): δ=9.92 (s, 1H), 8.30 (d,
J=8.7 Hz, 1H), 7.94 (s, 1H), 7.71 (d, J=7.7 Hz, 1H), 7.61–7.21 (m,
12H), 6.77 (d, J=9.0 Hz, 1H), 6.73 (s, 1H), 5.19 (s, 2H), 5.14 (s, 2H),
4.37 (q, J=7.1 Hz, 2H), 1.39 (t, J=7.1 Hz, 3H).
Ethyl 3-(3,4-bis-(benzyloxy)benzamido)benzoate (22): Compound
22 was synthesized according to the general procedure using 17
(0.10 g, 0.30 mmol), but was not extracted. Instead the solvent of
the reaction mixture was evaporated under reduced pressure and
the residue directly purified by column chromatography. The
desired product was obtained as a yellow solid (0.14 g, 0.28 mmol,
93%). 1H NMR (400 MHz, CDCl3): δ=8.09 (s, 1H), 8.03 (d, J=8.1 Hz,
1H), 7.99 (s, 1H), 7.80 (d, J=7.7 Hz, 1H), 7.55 (d, J=2.0 Hz, 1H), 7.48–
7.27 (m, 12H), 6.93 (d, J=8.4 Hz, 1H), 5.21 (s, 2H), 5.19 (s, 2H), 4.36
(q, J=7.1 Hz, 2H), 1.38 (t, J=7.1 Hz, 3H).
Ethyl 3-(3,5-bis-(benzyloxy)benzamido)benzoate (23): Compound
23 was synthesized according to the general procedure (but
extracted with CH2Cl2 instead of EtOAc), using 18 (0.17 g,
0.50 mmol) and was obtained as a white solid (0.09 g, 0.02 mmol,
36%). m/z (ESI+) [M+H]+ C30H28NO5 calculated 482.2 Da, found:
482.8 m/z.
General procedure for the preparation of compounds 1,3, and
6via O-benzyl-deprotection: To a mixture of the respective O-
benzyl-protected compounds in THF/MeOH (1 :1 v/v, 30 mL
mmol  1) was added palladium on active carbon (20 w%). The
resulting suspension was stirred at room temperature for 8 h under
H2 atmosphere (1 bar) and then filtered over Celite. The solvent was
evaporated under reduced pressure and the resulting crude
product purified by column chromatography on SiO2 (hexane/
EtOAc as eluent) to afford the desired compounds 1, 3 and 6.
Ethyl 3-(2,4-dihydroxy-benzamido)benzoate (1): Compound 1 was
synthesized according to the general procedure using 21 (0.05 g,
0.10 mmol) and was obtained as a grey solid (0.03 g, 0.10 mmol,
99%). 1H NMR (400 MHz, [D6]DMSO): δ=12.17 (br s, 1H), 10.35 (s,
1H), 10.25 (br s, 1H), 8.33 (t, J=1.9 Hz, 1H), 7.95 (ddd, J=8.1, 2.1,
0.9 Hz, 1H), 7.90 (d, J=8.8 Hz, 1H), 7.70 (dt, J=7.8, 1.2 Hz, 1H), 7.50
(t, J=7.9 Hz, 1H), 6.38 (dd, J=8.7, 2.3 Hz, 1H), 6.33 (d, J=2.3 Hz,
1H), 4.33 (q, J=7.1 Hz, 2H), 1.33 (t, J=7.1 Hz, 3H). HRMS (ESI+) [M+
H]+ C16H16NO5 calculated 302.1028 Da, found: 302.1027 m/z.
Ethyl 3-(3,4-dihydroxy-benzamido)benzoate (3): Compound 3 was
synthesized according to the general procedure using 22 (0.06 g,
0.13 mmol) and was obtained as a white solid (0.03 g, 0.11 mmol,
81%). 1H NMR (500 MHz, [D6]DMSO): δ=10.15 (s, 1H), 9.63 (br s,
1H), 9.27 (br s, 1H), 8.42 (s, 1H), 8.04 (d, J=8.0 Hz, 1H), 7.65 (d, J=
7.7 Hz, 1H), 7.46 (t, J=7.9 Hz, 1H), 7.41 (s, 1H), 7.38 (dd, J=8.2,
1.9 Hz, 1H), 6.83 (d, J=8.2 Hz, 1H), 4.32 (q, J=7.1 Hz, 2H), 1.33 (t,
J=7.1 Hz, 3H); 13C NMR (126 MHz, [D6]DMSO): δ=165.72, 165.44,
149.09, 145.01, 139.92, 130.24, 128.93, 125.51, 124.60, 123.79,
120.68, 119.77, 115.48, 114.92, 60.77, 14.21; HRMS (ESI+) [M+H]+
C16H16NO5 calculated 302.1028 Da, found: 302.1033 m/z.
Ethyl 3-(3,5-dihydroxy-benzamido)benzoate (6): Compound 6 was
synthesized according to the general procedure using 23 (0.09 g,
0.18 mmol) and was obtained as a grey solid (0.05 g, 0.15 mmol,
86%). 1H NMR (500 MHz, [D6]DMSO): δ=10.29 (s, 1H), 9.57 (s, 2H),
8.44 (t, J=1.9 Hz, 1H), 8.04 (ddd, J=8.2, 2.2, 1.0 Hz, 1H), 7.67 (dt, J=
7.7, 1.3 Hz, 1H), 7.47 (t, J=8.0 Hz, 1H), 6.80 (d, J=2.2 Hz, 2H), 6.43 (t,
J=2.2 Hz, 1H), 4.33 (q, J=7.1 Hz, 2H), 1.33 (t, J=7.1 Hz, 3H). 13C
NMR (126 MHz, [D6]DMSO): δ=165.93, 165.65, 158.36, 139.64,
136.72, 130.27, 128.94, 124.62, 124.05, 120.72, 105.86, 105.62, 60.75,
14.18; Anal. calcd for C16H15NO5 (301.3): C, 63.78; H, 5.02; N, 4.65;
found: C, 63.83; H, 5.02; N, 4.66%; HRMS (ESI+) [M+H]+ C16H16NO5
calculated 302.1028 Da, found: 302.1033 m/z.
Preparation of 1-(2,4-dihydroxyphenyl)-2-(3,4-dimethoxyphenyl)
ethan-1-one (5): To a solution of 2-(3,4-dimethoxyphenyl)acetic
acid (1.57 g, 8.00 mmol, 1 equiv) in boron trifluoride diethyl ether-
ate (15.84 mL, 56.00 mmol, 7 equiv) at 0 °C resorcinol (1.32 g,
12 mmol, 1.5 equiv) was added. The mixture was heated for 5 h at
110 °C and then cooled to 0 °C. Cold water (200 mL) was added, the
resulting precipitate collected by filtration, washed with water and
recrystallized from EtOH to afford 5 as a white solid (0.44 g,
1.52 mmol, 19%). 1H NMR (400 MHz, [D6]DMSO): δ=12.57 (s, 1H),
10.68 (s, 1H), 7.95 (d, J=8.9 Hz, 1H), 6.90 (d, J=1.9 Hz, 1H), 6.87 (d,
J=8.2 Hz, 1H), 6.79 (dd, J=8.2, 2.0 Hz, 1H), 6.39 (dd, J=8.8, 2.4 Hz,
1H), 6.25 (d, J=2.4 Hz, 1H), 4.19 (s, 2H), 3.72 (s, 3H), 3.71 (s, 3H); 13C
NMR (101 MHz, [D6]DMSO): δ=202.41, 164.95, 164.69, 148.60,
147.63, 133.61, 127.46, 121.53, 113.36, 112.15, 111.85, 108.26,
102.49, 55.50, 55.47, 43.69; HRMS (ESI+) [M+H]+ C16H17O5 calcu-
lated 289.1076 Da, found: 289.1074 m/z.
Biological validation
Cell culture: Human embryonic kidney (HEK)-Blue hTLR2 cells
(InvivoGen, Touluse, France) were used from passage 5 to 20.
Stimulation of the cells with TLR2 agonists leads to production and
secretion of NF-kB-inducible embryonic alkaline phosphatase
(SEAP). The enzyme transforms the substrate QUANTI-Blue (Inviv-
oGen) into a blue dye that was detected by optical density (OD) at
640 nm as previously described.[11a,12] THP-1 cells (DSMZ, Braunsch-
weig, Germany) from passage 10 to 15 were cultured as previously
reported.[13] For the generation of THP-1 macrophages, THP-1
monocytes were first incubated with 25 ng/mL Phorbol 12-
myristate 13-acetate (PMA, Sigma-Aldrich) for 48 h and afterwards
rested for 24 h. The cell lines were cultured at 37 °C in a humidified
atmosphere of 5% CO2 and 95% air and were regularly tested
negative for mycoplasma contamination (VenorGeM Classic Myco-
plasma PCR detection kit, Minerva Biolabs, Berlin, Germany).
TLR2 ligands: The synthetic lipopeptides Pam3CSK4 and Pam2CSK4,
lipopolysaccharide from Escherichia coli O111:B4 (LPS-EB), flagellin
from Salmonella typhimurium (FLA-ST), the thiazoloquinoline com-
pound CL075 and class B CpG oligonucleotide ODN2006 were
purchased from Invivogen and the TLR2 antagonist CU-CPT22 was
obtained from Sigma-Aldrich.
Cell stimulation: HEK-Blue hTLR2 cells (4×104 cells/well) and THP-1
macrophages (2×105 cells/well) were cultured in 96-well plates and
24-well plates (TPP, Trasadingen, Switzerland). After cells were
washed with phosphate-buffered saline (PBS, Sigma-Aldrich), cell
stimulation was done in OptiMEM (ThermoFisher Scientific). The
tested compounds and CU-CPT22 (50 mM) were dissolved in
DMSO. Final DMSO concentrations in cell culture were below 0.2%
(v/v). Vehicle controls showed no significant difference to non-
stimulated controls (data not shown). For co-stimulation of TLR2
agonists and tested modulators, cells were preincubated with the
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ELISA: Commercially available ELISA kits were used for detecting
human IL-8 levels in cell culture supernatants (ELISA-Ready Set Go,
Invitrogen by Thermo Fisher Scientific).
Cell viability: Cell viability was assessed by the MTT assay in HEK
Blue hTLR2 cells as previously described.[14] 10% (v/v) DMSO (Carl
Roth) served as control and the viability of untreated cells was
defined as 100%.
Statistical analysis: Data of the bar charts are shown as mean+SD.
Potency (IC50) data are presented as mean with the confidence
interval (95%). Statistical analysis was done by using GraphPad
Prism 6.0 (GraphPad software, San Diego, USA). Nonlinear regres-
sion was used to plot and analyze concentration-response curves
and to obtain IC50 values.
Computational methods: The crystal structure of the heterodimer
of TLR2-TLR1 with bound Pam3CSK4 (PDB ID: 2Z7X)
[15] was retrieved
from the Protein Data Bank[16] and used for docking studies with
the tested compounds. Prior to docking the TLR1 monomer, all
ligands and water molecules were removed using Molecular
Operating Environment (MOE2019, Chemical Computing Group,
Montreal, QC, Canada). The TLR2 monomer was protonated using
the “Protonate 3D” application included in MOE2019. The GOLD
Suite v.5.2 (Cambridge Crystallographic Data Centre, Cambridge,
UK)[17] was used for docking with the GoldScore[18] as scoring
function with “slow” parameters. Binding poses were minimized
(MMFF94 force field)[19] and further analyzed in LigandScout 4.2
(Inte:ligand, Vienna, Austria).[20]
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